Table 2.
Levels blood biomarkers
| Biomarkers | T1 (n = 98) | T2 (n = 37) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SSc (n = 67) | SSc-ILD (n = 31) | Sig. | SSc (n = 27) | SSc-ILD (n = 10) | Sig. | |||||
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |||
| MMP-9 | 820.5 | 435-1354 | 1243.4 | 887-1724 | * | 1164.9 | 389-1599 | 903.14 | 366-1647 | |
| IGFBP-1 | 14.96 | 8.6-25.5 | 5.74 | 2.2-14.3 | *** | 11.04 | 7.3-24.6 | 5.6 | 2.7-33.1 | |
| H3.1 | 66.4 | 41-102 | 82.6 | 65-146 | * | 56.2 | 41-79 | 77.6 | 55-172 | * |
The levels of IGFBP-1, MMP-9, and H3.1 containing cf-nucleosomes (median and IQR) were evaluated at T1 and T2 for SSc and SSC-ILD patients. Significant differences were observed between SSc and SSc-ILD patients for all three biomarkers at T1. At T2, only the level of H3.1 containing cf-nucleosome remained significantly higher in SSc-ILD patients
P values were determined by Mann-Whitney rank-sum test